Showing 5561-5570 of 8887 results for "".
- AD Pipeline Watch: Eblasakimab Monthly Dosing Shows Promise in Phase 2b AD Studyhttps://practicaldermatology.com/news/eblasakimab-monthly-dosing-shows-promise-in-phase-2b-ad-study/2461845/ASLAN Pharmaceuticals’ eblasakimab met the primary endpoint of percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 16 versus placebo in adult patients with moderate-to-severe atopic dermatitis (AD), according to results from the Phase 2b dose-ra
- Biosimilar Update: Fresenius Kabi’s Idacio Joins Growing List of Available Humira Biosimilarshttps://practicaldermatology.com/news/biosimilar-update-fresenius-kabis-idacio-joins-growing-list-of-available-humira-biosimilars/2461836/Fresenius Kabi’s citrate-free adalimumab biosimilar
- TikTok Trend Watch: Browning Lotions and Summer Tanshttps://practicaldermatology.com/news/tik-tok-trend-watch-browning-lotions-and-summer-tans/2461830/Skinfluencers on social media are praising browning lotions for perfecting their summer tans. What is browning lotion? Browning lotion or tanning accelerators work with the sun's UV rays to darken your skin faster. What could go wrong?
- Merz Aesthetics to Distribute AccuVein’s Visualization Systemhttps://practicaldermatology.com/news/merz-aesthetics-to-distribute-accuveins-visualization-system/2461829/Merz Aesthetics is now the sole authorized distributor of AccuVein’s vein visualization system in the U.S. aesthetics market. A limited initial AccuVein field pilot yielded positive results and significant expansion of both new customers and Merz Aesthetics portfolio adoption. Bas
- Dermatology Around the Globe: First JAK for AD Approved in Indiahttps://practicaldermatology.com/news/dermatology-around-the-globe-first-jak-for-ad-approved-in-india/2461828/Intas Pharmaceuticals Ltd launched TOFATAS –a Drugs Controller General of India (DCGI) -approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above experiencing flare-ups of the disease. "The
- Open Enrollment Underway for Phase 2b Trial of Topical AMTX-100 CF3 in ADhttps://practicaldermatology.com/news/open-enrollment-underway-for-phase-2b-trial-of-topical-amtx-100-cf3-in-ad/2461827/Amytrx Therapeutics is enrolling mild to moderate atopic dermatitis patients for its Phase 2b clinical trial of a topical formulation of AMTX-100 CF3. Eligible adults interested in participating or learning more about the trial are encouraged to visit the
- Fifth Piece of Art Added to Boehringer Ingelheim, FIT's DTech Unwearable Collectionhttps://practicaldermatology.com/news/fifth-piece-of-art-added-to-boehringer-ingelheim-fits-dtech-unwearable-collection/2461825/In partnership with the Fashion Institute of Technology's (FIT) DTech Lab and world-renowned designer, Bart Hess, Boehringer Ingelheim is introducing a fifth piece to The Unwearable Collection, an art collection that uses raw materials like paper and glass to uniquely illustrat
- Spotlight on the Skin of Color Societyhttps://practicaldermatology.com/news/spotlight-on-the-skin-of-color-society/2461823/It’s almost the Skin of Color Society’s (SOCS) 20th anniversary, and the group will be celebrating with several signature programs and new initiatives aimed at bringing greater diversity to dermatology, reducing healthcare disparities, advancing research, expanding training and m
- Oro Health, Dermago Unveil Consumer Version of its AI-powered Dermatology Assessment and Recommendation Toolhttps://practicaldermatology.com/news/oro-health-dermago-unveil-consumer-version-of-its-ai-powered-dermatology-assessment-and-recommendation-tool/2461822/Oro Health and Dermago are unveiling the public version of DermSmart, a tool designed to classify skin types and minor skin conditions. This new AI-driven version offers patients the ability to upload pictures of their skin condition, ask questions and interact with the tool i
- Scleroderma Research Update from Cedars-Sinai’s Kao Autoimmunity Institutehttps://practicaldermatology.com/news/scleroderma-research-update-from-cedars-sinais-kao-autoimmunity-institute/2461818/An estimated 100,000 people in the U.S. are living with scleroderma, an autoimmune disease characterized by thickening and scarring of the skin and vital organs, and the narrowing of the blood vessels which lead to poor circulation. Tthere are about 7,000 to 8,000 new cases every year.